Hengrui Medicine
Hengrui Medicine
iangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medicine packing materials.
Hengrui Medicine, founded in April, 1997 and headquartered in Lianyungang, is an innovative pharmaceutical developer. The founder is Zhou Yunshu. Listed on the SSE on October 18, 2000, the company's major shareholders are Jiangsu Hengrui Pharmaceutical Group Co., Ltd., Tibet Dayuan Enterprise Management Co., Ltd. and Hong Kong Securities Clearing Co., Ltd.. Rivals that have direct and indirect competition with Hengrui Medicine include Harbin Pharmaceutical, Yunnan Baiyao, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
In-depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Technology, Real Estate, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Technology, Real Estate, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Apr 25, 2022 06:25 PM
· Healthcare
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
Briefing Apr 25, 2022 09:45 AM
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Healthcare
Dialysis Provider Dakang Medical Raised CNY 400 Million Yuan in Series E Round.
This financing round was led by Ganjiang Kai Investment, a state-owned investment platform in Ganjiang, Jiangxi Province, and was followed by Central Enterprises Poor Regions Industry Investment Fund Co., and Neovision Capital.
Yesterday 04:16 PM
Healthcare · Analysis
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Briefing Mar 14, 2022 07:48 AM
· Healthcare
Defining key tasks and accelerating the construction of new urbanization
See more
Related Companies
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.